Quince Therapeutics Acquires Orphai Therapeutics in $187M Private Placement Deal
Quince Therapeutics (QNCX) has acquired clinical-stage biotechnology company Orphai Therapeutics, gaining access to its lead program LAM-001. The deal includes a private placement of up to $187 million aimed at advancing Quince's pulmonary disease pipeline.
Tickers: $QNCX